EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
news

Roche trial win for Tecentriq leaves questions unanswered

(Credit: Roche ) Roche on Monday said its immunotherapy Tecentriq helped stave off tumor growth in a Phase 3 study of previously untreated people with metastatic...
Continue Reading →
news

Regulators, Gilead at odds over HIV drug’s use in women

(Credit: Wikimedia Commons ) Food and Drug Administration staff appear confident an HIV treatment developed by Gilead can also help prevent the disease from spre...
Continue Reading →
news

FDA approves first therapy for rare joint tumor

Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial gi...
Continue Reading →
Europe

Experts Predict Chat Bots and Virtualisation as On-Trend

Employee Benefits Swing Towards Individual Well Being - Summer 2019 HSC, the critical illness support specialists, have launched a new trends report for Summer 201...
Continue Reading →
Europe

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement

Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. ("Ono") announced today the three companies have entered into a clinical collaborat...
Continue Reading →
Europe

Novartis’ Kisqali sharpens survival edge with second ph3 win

Novartis will unveil details from Kisqali's latest phase 3 win at an upcoming medical meeting. (Novartis) In June, Novartis’ Kisqali showed it could prolong the ...
Continue Reading →
Europe

Chasing Pfizer and J&J, Bayer’s Nubeqa nabs fast FDA nod in prostate cancer

Eyeing Xtandi and Erleada, Bayer and Orion's Nubeqa has won FDA approval in non-metastatic castration-resistant prostate cancer market. (Bayer) Pfizer and Astell...
Continue Reading →
Europe

J&J advances MS drug candidate toward US, EU markets

An experimental drug developed by Johnson & Johnson for multiple sclerosis succeeded in a head-to-head study against Sanofi's on-market therapy Aubagio, accor...
Continue Reading →
news

Novartis heart drug misses on potentially billion-dollar market

(Credit: Novartis ) After five years of testing, Novartis said Monday its heart medication Entresto "narrowly" failed a study that could have added a valuable in...
Continue Reading →
news

Lilly cancer push boosted by survival benefit to key drug

(Credit: Eli Lilly & Co. ) Nearly two years after the first U.S. approval of Eli Lilly's breast cancer drug Verzenio, the company said Tuesday interim data f...
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18